Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $8 | $8 | $6 | $1 |
| % Growth | -2.4% | 37.5% | 354.7% | – |
| Cost of Goods Sold | $0 | $62 | $73 | $76 |
| Gross Profit | $8 | -$54 | -$67 | -$74 |
| % Margin | 100% | -681.4% | -1,176.4% | -5,904.4% |
| R&D Expenses | $57 | $62 | $73 | $76 |
| G&A Expenses | $18 | $23 | $23 | $18 |
| SG&A Expenses | $18 | $23 | $23 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | -$62 | -$73 | -$76 |
| Operating Expenses | $81 | $23 | $23 | $18 |
| Operating Income | -$73 | -$76 | -$90 | -$93 |
| % Margin | -949.9% | -967.4% | -1,576.6% | -7,364.1% |
| Other Income/Exp. Net | $10 | $7 | $2 | -$6 |
| Pre-Tax Income | -$63 | -$69 | -$88 | -$99 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$63 | -$69 | -$88 | -$99 |
| % Margin | -820.8% | -878.6% | -1,537.8% | -7,824.7% |
| EPS | -1.65 | -1.83 | -2.3 | -2.79 |
| % Growth | 9.8% | 20.4% | 17.6% | – |
| EPS Diluted | -1.65 | -1.83 | -2.3 | -2.79 |
| Weighted Avg Shares Out | 38 | 38 | 37 | 37 |
| Weighted Avg Shares Out Dil | 38 | 38 | 37 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $7 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $1 |
| EBITDA | -$66 | -$74 | -$89 | -$92 |
| % Margin | -864.2% | -943.9% | -1,547.5% | -7,269.4% |